Practical Guidance on the Clinical Management of Ocular Adverse Events Associated with Belantamab Mafodotin for Patients with Relapsed/Refractory Multiple Myeloma: Latin American Expert Panel Recommendations

Abstract Multiple myeloma is a significant cause of mortality worldwide, and although changes in the treatment landscape have improved outcomes overall, many patients become refractory to standard therapies. In Latin America, outcomes are especially poor, further compounded by access and equality ba...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Vânia Hungria, Virginia Abello Polo, Ariel Corzo, Edvan Q. Crusoe, Michel E. Farah, Natália A. Iutaka, Gracia A. Martinez, Aline G. Ramírez Alvarado, Simón Romano-Bucay, Patricio G. Schlottmann, Cristian M. Seehaus, Jorge C. Torres Flores, Angelo Maiolino
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Adis, Springer Healthcare 2025-07-01
Sarja:	Oncology and Therapy
Aiheet:	Belantamab mafodotin Clinical management Latin America Multiple myeloma Ocular adverse events
Linkit:	https://doi.org/10.1007/s40487-025-00354-2
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!